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1. Introduction
Hepatic resection is a commonly performed procedure for a variety of malignant and benign
hepatic tumours [1, 2]. Historically, liver resection, irrespective of the indication, was associ‐
ated with a high morbidity and mortality [2-4]. During the last decades however, perioperative
outcome after hepatic resection has improved, due to increased knowledge of liver anatomy
and function, improvement of operating techniques and advances in anaesthesia and postop‐
erative care [1, 3, 4].
Hepatic resectional surgery is possible since the liver has the ability to regenerate. Although
it is doubtful whether the ancient Greeks already appreciated this unique quality of the liver,
it was first described in the myth of Prometheus (Προμηθεύς): he enraged the Gods for his
disrespect (ὕβρις) after climbing the Mount Olympus and stealing the torch in order to give
fire to the humans. He was punished by Zeus and chained to a rock in the Kaukasus Mountains.
Every couple of days, an eagle came and ate part of his liver. As the liver regenerated every
time, the eagle returned again and again to eat the liver and thereby torture poor Prometheus
(figure 1). With this ancient knowledge it was considered possible to take parts of the liver, as
this organ has enough capacity to work with a smaller part and is able to regenerate.
Apart from the eagle, no human dared to remove a part of the liver. In the ancient period of
the Assyrian and Babylonian cultures of 2000 - 3000 BC the liver played an important role to
predict the future by reading the surface of sacrificed animals [5]. This was also common in
the Etruscan society, where the haruspices predicted the future from sheep livers. Hippocrates
(460-377 BD), one of the founding fathers of ancient medicine, produced not only an oath with
ethical rules, which is still used in modern times for all doctors. His careful observations also
led to the recommendation to incise and drain abscesses of the liver with a knife [5]. Celsus
documented the treatment of exposed liver in war wounds. Although he was not a physician,
© 2013 Stoot et al.; licensee InTech. This is an open access article distributed under the terms of the Creative
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he described his observations in the first century AD from the Alexandrian school led by
Herophilus of Chalcedon and Erisastratus of Chios [5]. In the same era, the Greek Galen became
one of the emperor’s physicians in Rome and wrote reports about the dissection of many
species of animals, including primates. He described the central role of the liver in absorption
and digestion and his work remained of great importance for the coming centuries [5]. In the
centuries thereafter many reports were produced describing the treatment of war or trauma
wounds.
Figure 1. Prometheus chained (243 x 210 cm), Peter Paul Rubens, ca. 1611-1618, Philadelphia, Philadelphia Museum
of Art.
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Glisson performed extensive investigations of the vascular anatomy in 1654 (figure 2) [6]. It
took more than two centuries before his work was rediscovered and further clarified by Rex
(1888) in Germany and Cantlie (1897) in England [5, 7]. These contributions led to the division
of the liver in a left and right lobe [5].
Figure 2. Francis Glisson (1599-1677).
2. History of hepatic surgery
It still took 17 centuries before Hildanus successfully performed the first partial liver resec‐
tion for trauma [8]. The introduction of ether anaesthesia (1846) and the growing knowledge
of antisepsis (1867) made successful elective abdominal operations possible (table 1) [5].
Langenbuch was the first to perform a successful elective liver resection in 1887 (figure 3)
and Wendel did the first hemihepatectomy in 1911 [8]. The principles of liver haemostasis
and regeneration were determined in the period 1880-1900 [8]. The knowledge of the princi‐
ple of inflow and outflow of the liver and vascular control was one of the major advance‐
ments. Before that, wedge resections and mattress sutures were mostly used. This insight of
inflow and outflow reduction was marked by the publication of James Hogart Pringle of
Glasgow, Scotland (figure 4) [9]. He described the idea of digital control of the hilar liga‐
ment to reduce liver haemorrhage. In his famous report (1908) on liver haemorrhage after
trauma, eight patients were included. Three died before the operation, one refused the oper‐
ation and all four operated patients died; two died during the operation and two shortly
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thereafter [5, 9]. However, his idea of digital vascular control of the hilum was more success‐
ful in the laboratory setting, where he operated three rabbits with better results, which led to
his publication. Nowadays, more than a century later, the ‘Pringle manoeuvre’ or ‘Pringle’s
pinch’ is still used worldwide in hepatic resectional surgery and taught to all young sur‐
geons to control haemorrhage of the liver.
1846 Introduction of Ether anaesthesia Morton
1863 Bacterial fermentation of wine Pasteur
1867 Antisepsis Lister
1870 First successful excision of section of the liver Bruns
1880 Discovery of Streptococci, staphylococci and pneumococci Pasteur
1881 First successful gastrectomy Billroth
1882 First successful cholecystectomy Langenbuch
1883 First human colon anastomosis Billroth and Senn
1884 Pancreas excised for cancer Billroth
1886 Report on appendicitis Fitz
Introduction of sterilisation by steam Von Bergmann
First elective liver resection for adenoma Lius
1887 First successful elective liver resection Langenbuch
1887 Successful packing of stabwound of liver Burckhardt
1888 First successful laparotomy for traumatic liver injury Willet
Table 1. Advances in the beginning of surgery [5].
Figure 3. James Hogarth Pringle (1863-1941).
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Figure 4. Carl Langenbuch (1846-1901).
Liver surgery became gradually more popular as a better understanding of anatomic segments
was established after the work of Couinaud [10]. The classic morphological (outside) anatomy
with two main lobes (left and right) was extended by the internal hepatic anatomy with several
independent functional segments (figure 5). Each hepatic segment consists of liver parenchy‐
ma with an efferent hepatic vein branch and a portal triad; a hepatic artery branch, an afferent
portal vein, and an efferent bile duct. The classic right lobe consists of four segments, the left
lobe consists of three segments and the caudate lobe is segment 1.
With knowledge of the segmental anatomy of the liver, a safe transection plane could be chosen
for resection without excessive blood loss and without necrosis of remnant liver. This specific
anatomy of independent functional segments made it possible to resect parts of the liver
without compromising the hepatic function of remnant segments. Moreover, as already
described by the myth of Prometheus, the liver has regeneration capacity in contrast to other
human organs. In other words after partial resections, the liver can recover its mass and
function. The term ‘function of the liver’ is actually a collective term for a range of functions
including amongst others ammonia detoxification, urea synthesis, bile synthesis and secretion,
protein synthesis, gluconeogenesis and clearance or detoxification of drugs, bacterial toxins
and bacteria [11]. As the liver is the main detoxifying organ in humans, adaptation of its
function is crucial to survive. Regeneration however, takes time. After liver surgery with a
reduction of the hepatic cell mass, a ‘survival programme’ may start for vital liver functions
[12]. Some of these functions are increased rapidly in the remnant liver after resection [13]. In
the light of major hepatic resections, it is conceivable that too little functional liver remnant
may lead to liver failure, a lethal complication of liver surgery.
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Figure 5. The anatomy of the liver with separate segments following Couinaud’s classification. In this drawing only
major venous vessels are displayed (portal vein, caval vein and hepatic veins).
3. Resectional hepatic surgery
Hepatobiliary surgery incorporates a wide range of indications for surgical treatment of the
liver, varying from biopsy and resection to liver transplantation. The most important indica‐
tions for surgical treatment are liver lesions: these comprise a wide range of both benign and
malignant lesions, which can be either primary tumours (hepatocellular carcinoma) or
secondary tumours (i.e. metastases). Also, some infectious diseases of the liver (such as
echinococcosis) may be an indication for surgery. Irreversible liver dysfunction caused by
acute or chronic liver diseases, may be an indication for transplantation of the liver. Other
benign diseases of the liver such as symptomatic simple cysts and Polycystic Liver Disease
(PCLD) may also warrant surgical treatment. Other reasons for surgery of the liver may be
after severe injury or trauma of the liver. The latter indications are beyond the scope of this
chapter. Since hepatic lesions form the main surgical indication for hepatic diseases, the focus
will be on resectional liver surgery.
3.1. History of hepatic surgery for malignant lesions
The report of the first anatomical right hepatectomy for cancer by Lortat-Jacob in 1952 marked
a new era in liver surgery [14]. In the beginning, however, blood loss and mortality were
considerable. A multicentre analysis in 1977 of more than 600 hepatic resections for various
indications showed an operative mortality of 13%, which rose to 20% for major resections [15].
Despite this, pioneers in liver surgery continued the quest for improving this challenging field
of expertise and gradually mortality decreased to 5.6% [16]. The 5 year survival rates have
Hepatic Surgery6
increased from 20% in the beginning [16, 17] to as high as 67% in selected patients [18]. Earlier
developments in liver surgery have been marked by major contributions of Starzl (USA),
Bismuth (France) and Ton That Tung (Vietnam) [19-22]. With better knowledge of the
segmental anatomy, it was shown that parenchyma-sparing segmental resections were equally
effective as classic lobar resections, and in this way more functional remnant liver was
preserved [3, 23, 24]. Also, anaesthetic care and liver transection techniques were modernized
and improved over time [1, 3, 4, 25, 26].
Over the last decades, it was shown in several large series that perioperative results became
more encouraging, with operative mortality rates less than 5% in high volume centres [3, 24,
25]. Due to these improvements in liver surgery which not only proved to prolong life but also
to be a potentially curative treatment option for primary and metastatic cancers [27, 28], liver
surgery became standard of care for selected patients with primary and secondary hepato‐
biliary malignancies. Moreover, with the increasing improvements in the safety of hepatic
resections, this evolved to the most effective treatment for some benign diseases [29].
It is hard to pinpoint one discriminating factor that made the improvements in outcome
possible [3]. Many factors contribute to the gradually improved outcome. Most important
factors in this regard are probably the better knowledge of hepatic anatomy and thus ana‐
tomically  based  resections,  better  patient  selection,  general  improvements  in  operative
and anaesthetic  care and the development of  hepatobiliary surgery as a  distinct  area of
specialisation [3].
3.2. Transection techniques in hepatic resection
Parenchymal transection is the most challenging part of liver resection. Due to the complicated
vascular and biliary anatomy of the liver, haemorrhage is a great risk [30-35]. The firstly
performed liver resections failed as a consequence of haemorrhage or patients died shortly
after because of bleeding [31]. Before the 1980s, mortality after hepatic resection was 10 to 20%
and haemorrhage was a common cause [30]. Moreover, blood transfusion in the perioperative
period is associated with poorer outcome in the long term [33]. In contrast to patient- or
tumour-related factors, surgical techniques can be changed in order to prevent blood loss and
transfusion.
Parenchymal division was first described in 1958 when Lin and colleagues introduced the
finger fracture technique (digitoclasy) in which liver tissue is crushed between the surgeon’s
fingers [30]. Vessels and bile ducts are exposed, identified and then divided. Soon this
technique was improved by using surgical clamps (i.e. Kelly clamp) and called the crush-clamp
technique [30, 31]. Division of the vessels and bile ducts can be achieved by suture ligation,
bipolar electrocautery, vessel sealing devices or vascular clips. It is frequently combined with
intermittent inflow occlusion by portal triad clamping (Pringle maneuver) [31].
Subsequently, many transection techniques have been developed in order to improve results.
The Cavitron Ultrasonic Surgical Aspirator (CUSA, Tyco Healthcare, Mansfield, MA, USA)
combines ultrasonic energy with aspiration and results in a more precise transection plane.
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Vessels and bile ducts are exposed and can then be divided with a method according to the
surgeon’s preference [30, 31]. In a recent study, liver parenchyma transection using CUSA was
associated with higher numbers of potentially dangerous air embolism although patients did
not show clinical symptoms [36]. The Harmonic Scalpel (Ethicon Endo-Surgery, Cincinnati,
OH, USA) is comparable to the CUSA, but it uses ultrasonic shears and vibration to cut through
the parenchyma. It instantly coagulates blood vessels by protein denaturation and is mainly
used in laparoscopic procedures, because of the difficulties using the other transection
instruments in this setting. The hydro or water jet uses a high-pressure water jet to dissect liver
parenchyma and expose vessels and bile ducts after which they can be divided. Like with the
Harmonic Scalpel, less thermal damage is caused. In radiofrequency-assisted liver resection
radiofrequent electrodes are inserted in the transection plane and radio frequent energy is
applied for one to two minutes, followed by transection of the coagulated liver using a
conventional scalpel. [30, 31].
In a review including seven randomized controlled trials with a total of 556 patients, the clamp-
crush technique was quicker and associated with lower rates of blood loss and transfusion
compared with CUSA, hydrojet and radiofrequency dissecting sealer. No significant differ‐
ences in mortality, morbidity, liver dysfunction, ICU stay and length of hospital stay were
found. The crush-clamp technique comes with low costs and does not need any extra advanced
tools. However, not all techniques in the trials were combined with vascular occlusion. This
may have led to a bias in favour of the clamp-crush technique [32, 34]. The CRUNSH trial will
demonstrate whether vascular stapling is superior to the crush-clamp method in elective
hepatic resection [37]. Palavecino and colleagues developed the so-called ‘two-surgeon
method’, combining a saline-linked cautery and an ultrasonic dissector. Exposure of vessels
and biliary ducts and haemostasis are performed simultaneously. Retrospectively, signifi‐
cantly lower transfusion rates were seen [33].
In conclusion, the clamp-crush technique seems to be superior especially as it is an easy method
and comes with low costs. It might be regarded as the golden standard with which new devices
or methods should be compared. However, high-quality randomized controlled trials are
missing. Besides, the surgeon’s experience plays an important role. Because of this, one could
say that the method of choice is the clamp-crush technique and other techniques can be applied,
or combined, dependent on the surgeon’s experience and preference.
3.3. Malignant lesions
The liver has an important function as a detoxifying organ and due to the anatomical position
in the abdomen; most gastro-intestinal organs drain their venous blood to the liver. This makes
the liver a frequent location of metastases from a variety of intra-abdominal and sometimes
even extra-peritoneal primary cancers. Also, primary cancers can arise in the liver. Of these
the hepatocellular carcinoma is the most common malignancy. With a normal functioning
liver, resection is the treatment of choice for most of these malignant lesions.
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Metastases of colorectal origin are the most frequent malignant lesions in the liver. With near‐
ly one million new cases diagnosed each year and around half a million deaths annually, color‐
ectal cancer is one of the most common causes of cancer related death worldwide [38]. Over
half of the patients with colorectal cancer will develop liver metastases [39]. Moreover, up to
25% of these patients present with liver metastases at the same time of the primary diagnosis
[40]. Colorectal liver metastases may therefore be regarded as a major health problem [39].
The only chance of long-term survival in patients with liver metastases is provided by re‐
section of these liver metastases, with 5-year survival rates around 30-40% [41]. Until re‐
cently,  however,  few  patients  with  malignant  liver  lesions  were  considered  for  partial
hepatic resection. Due to the restricted resection criteria, only 10-20% of the patients with
malignant  lesions  were  selected.  Palliative  chemotherapy was  offered for  the  remaining
proportion of  the patients,  resulting in a median survival  of  6-12months [8,  42].  Due to
the increased safety of liver surgery, liver resection is currently also used for other meta‐
stases such as neuroendocrine tumours [43], sarcoma’s [44], melanoma [45-47], gastric can‐
cer [48-50] and breast cancer [48, 51, 52].
The selection criteria for liver resections were initially fairly strict:  unilobar distribution,
less  than four metastases,  maximum tumour size of  5  cm and tumour free margin of  1
cm. These resection criteria have been evaluated over time and have gradually been aban‐
doned, as these appeared to be not as important as previously assumed [53-55]. Even in
elderly patients and poor prognostic groups, complete tumour resection results in a good
long-term survival [56-58].
In the treatment of malignant liver disease, many improvements have been developed in recent
years: new surgical strategies for safer resection (including two stage hepatectomy and portal
vein embolisation), more effective chemotherapy, and additional techniques such as local
ablation therapies to increase possible curative treatment [59-64]. The combination of these
developments has led to an important progress and has resulted in more patients being
considered suitable for liver resection to almost 30% [62]. Better survival of patients with
primary or metastatic liver cancer has been reported in recent years and liver resection is
currently the only potentially curative treatment option.
3.4. Benign hepatic lesions
In case of malignant hepatic disease, surgical resection is currently felt justified despite a
morbidity and mortality, which may be as high as 42% and 6.5% respectively [1, 3, 65-67]. In
case of benign hepatic disease, however, this decision remains more difficult. Due to the
widespread use of imaging modalities such as ultrasonography, computed tomography (CT),
and magnetic resonance imaging (MRI), benign hepatic masses are increasingly being
identified. However, not all benign hepatic tumours require resection. Careful diagnosis with
contrast enhanced CT or MRI needs to be performed first. Benign lesions can grossly be divided
in solid and non-solid lesions (table 2).
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Solid lesions Symptoms Treatment
Hepatocellular adenoma Variable: from incidental finding to severeabdominal pain and shock in case of rupture
<5cm watchful waiting, stop
oral contraceptives
≥5cm resection to prevent
rupture and malignant
degeneration
Focal Nodular Hyperplasia Mostly incidental finding Surgery rarely indicated
Angiomyolipoma Mostly incidental finding Surgery rarely indicated
Nodular regenerative
hyperplasia
Mostly asymptomatic, should be considered in
patients with clinical signs of portal hypertension
without evidence of cirrhosis
No proven treatment
Non-solid lesions
Simple hepatic cyst Variable: from incidental finding to abdominalpain
Surgery indicated only in case
of symptoms
Biliary cystadenoma Variable: from incidental finding to abdominalpain
Surgery may be indicated
(malignant degeneration)
Biliary hamartoma None Surgery not indicated
Cavernous haemangioma Variable, depending on size Surgery rarely indicated
Hydatid disease Variable: from incidental finding to severeabdominal pain and shock
Surgery indicated to relieve
symptoms and to prevent
rupture
Table 2. Most important benign liver lesions, divided in solid and non-solid lesions.
3.5. History of hepatic surgery for benign lesions
The first case of surgical resection for a presumably benign liver tumour was described in 1886
by Antonio Lius in Italy [68]. Lius was the assistant of Theodore Escher who excised a
pedunculated adenoma with the size of a child’s head (15.5 cm in greatest diameter) from the
left liver lobe of 67-year-old women. An uncontrollable bleeding was encountered during the
operation and the patient died several hours following surgery. The German surgeon Von
Langenbuch was the first to perform a successful resection of a benign solid pedicled liver
mass weighing 370 gram of the left liver in a 30-year-old woman who complained of abdominal
discomfort in the years following her first child’s birth in 1887 [69]. Postoperatively, secondary
haemorrhage occurred due to a bleeding hilar vessel. This was managed at re-exploration and
the patient survived. The course of symptoms and events in the latter case suggests the tumour
was most likely a hepatocellular adenoma.
It is nowadays well established that small benign lesions compatible with a diagnosis of
haemangioma, focal nodular hyperplasia (FNH) or hepatocelular adenomas (HCAs) are no
indication for liver resection [53]. Hepatocellular adenomas are considered the most important,
albeit uncommon, benign tumours of the liver that mostly occur in women. They are known
for their increased risk of haemorrhage and malignant transformation into hepatocellular
carcinoma (HCC) if size exceeds 5 cm. Therefore, surgical resection of HCAs is recommended
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for larger lesions [53, 54]. Focal nodular hyperplasia and haemangiomas have not been
regarded as potentially premalignant lesions.
The first case report of malignant transformation of a HCA was published in 1981 by Tesluk
and Lawrie [70]. The patient was a 34–year-old female with a large HCA measuring 16 cm in
diameter. She first presented with tumour haemorrhage after which her oral contraceptive use
was discontinued and the tumour subsequently shrank to a stable 5 cm. Three years later a
partial hepatectomy was performed when the tumour had reverted to its size at first presen‐
tation. Histological analysis revealed a well-differentiated HCC. The patient died of sepsis five
weeks postoperatively.
Foster and Berman were the first to report an estimated risk of malignant transformation in
1994, as they found a frequency of 13% in their series of 13 patients [71]. More recently, a
systematic review of the literature of the past 40 years containing more than 1600 HCAs
worldwide identified 68 reports of malignant transformation resulting in an overall frequency
of 4.2% among all adenoma cases [72]. Nowadays several other risk factors for malignant
potential of HCAs apart from size have been identified [73-84]. These are listed in table 3.
Risk factors
Tumour size ≥5 cm
Presence of β-catenin activating mutation
Presence of liver cell dysplasia within HCA
Patients with glycogen storage disease
History of androgen or anabolic steroid intake
Male sex
Obesity/overweight
Table 3. Risk factors for malignant transformation of hepatocellular adenomas.
3.6. Surgical treatment of hepatocellular adenomas
The identification of several risk factors for malignant potential of HCAs in recent years,
provides better indications for surgical treatment of these presumably benign tumours. Also,
the Bordeaux adenoma tumour markers (table 4) have greatly contributed to the subtype
classification of HCAs and have given clearer insights into the pathological mechanism of
malignant evolvement [79]. More recently, MR imaging techniques have been shown to be of
value in identifying premalignant HCAs [85, 86]. These advances in risk factor stratification,
together with tumour subtyping prior to hepatic surgery, might aid in selecting HCAs at high
risk of malignant evolvement for surgical resection. Unfortunately, routine performance of
biopsy of an HCA has not been implemented yet owing to the risk of sampling error, bleeding,
needle-track tumour seeding and the difficult interpretation of β-catenin staining. However,
a change towards a more stringent selection process in the near future is inevitable and may
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imply a major reduction of the number of liver resections, and thus morbidity and even
mortality, in a selected group of predominantly young patients.
HCA type Frequency (%) Malignant transformation Markers
β-catenin activated 10-15 Yes β-catenin+/GS+
HNF1α inactivated 30-50 Rarely LFABP-
Inflammatory 35 No SAA+/CRP+
Unclassified 5-10 No None
CRP, C-reactive protein; GS, glutamine synthetase; HCA, hepatocellular adenoma; HNF1a, hepatocyte nuclear factor 1a;
LFABP, liver-fatty acid binding protein; SAA, serum amyloid A; +, positive; -, negative. Table adapted with permission
from Stoot et al. 2010 [72].
Table 4. Types of HCAs and their immunohistochemical markers.
Concerning the management of ruptured HCAs, emergency surgery is associated with high
morbidity and mortality rates [73, 85]. Although this treatment is still suggested by some
authors [86], the maximally invasive therapy of immediate liver resection has gradually been
abandoned. Many liver surgeons prefer conservative management of ruptured HCAs con‐
sisting of immediate resuscitation with laparotomy and gauze packing [74]. Selective arterial
embolisation for ruptured HCAs may be a valuable alternative although it has rarely been
reported [55, 63, 70, 72, 87].
In conclusion, hepatic resection for benign tumours is mainly reserved for HCAs at risk for
malignant evolvement or haemorrhage. Advances in pathological subtyping, radiological
imaging and risk stratification have led to new insights and aid in justifying hepatic resection
in a more selected population.
4. Advances in the surgical treatment of benign cystic lesions: hydatid
disease
Surgical treatment may also be indicated for infectious diseases of the liver such as benign
lesions caused by the parasitic infection called Echinococcosis. Human echinococcosis is a
zoonosis caused by larval forms (metacestodes) of Echinococcus (E.) tapeworms found in the
small intestine of carnivores. Two species are of clinical importance – E. granulosus and E.
multilocularis – causing cystic echinococcosis (CE) and alveolar echinococcosis (AE) in humans,
respectively [87]. Besides, in the beginning of the 20th century the so-called neotropical
echinococcosis species E. oligarthrus and E. vogeli were discovered to cause polycystic echino‐
coccosis (PE). E. vogeli causes disease similar to AE and E. oligharthrus has a more benign
character [88]. Echinococcosis is endemic worldwide in large sheep-raising areas including
Africa, the Mediterranean region of Europe, the Middle East, Asia, South America, Australia
and New Zealand [89-96]. Human cystic echinococcosis is one of the most neglected parasitic
Hepatic Surgery12
diseases in the world. In many endemic regions most infected patients suffer considerably
from this disease, usually because of the lack of treatment possibilities due to poor infrastruc‐
ture and shortage of equipment and drugs [97, 98]. The incidence of hydatid disease in Western
industrial nations is relatively low [93, 94, 99]. Migration and travelling has led to an increase
of the prevalence of this disease in Northern parts of Europe and North America [96, 100]. The
diagnosis of hepatic echinococcosis can be made with a combination of patients’ symptoms,
liver imaging findings, detection of Echinococcis-specific antibodies and microscopic or
molecular examination of cyst fluid. The most frequent site for cystic lesions is the liver (60%
of patients), followed by the lungs in about 20% of patients. The remaining lesions are found
throughout the body [92, 95, 99, 101, 102].
The natural course of this infection can be extremely variable [101]. The hepatic cysts can
spontaneously collapse, calcify or even disappear. These patients can remain symptom-free
for years. It is not uncommon that the cysts are detected when abdominal imaging is performed
for a different reason. On the other hand, the cysts can also steadily grow about 1-3 cm in
diameter per year [96, 99]. They do not tend to grow infiltratively or destructively, but pressure
or mass effects of the cysts can displace healthy tissue and organs. Thus, most patients present
with symptoms from mechanical effects on other organs or structures, which can lead to pain
in the upper right quadrant, hepatomegaly and jaundice, depending on the location and nature
of the cysts [91, 96, 99, 101]. Infection of the cysts can result in sepsis and/or the formation of
liver abscesses. A feared complication is rupture of hepatic hydatid cysts into the peritoneal
cavity. This can result in serious anaphylaxis, sepsis and/or peritoneal dissemination. The
content of the ruptured cyst can disseminate into the biliary tract leading to cholangitis or
cholestasis, but also to the pleurae or lungs leading to pleural hydatidosis or bronchial fistula,
respectively [91, 92, 102].
4.1. History of hepatic surgery for hydatid disease
Hydatid disease was already recognized by Hippocrates more than two millennia ago. This
benign disease has been shown to act as a malignant disease as it has the tendency to dissem‐
inate to other organs and to cause a devastating disease sometimes even leading to death. The
serious effects of this disease were known in the late 1880s, when Loretta performed the first
left lateral liver resection for echinococosis in Bologna [8]. Last years many developments have
improved the course of hydatid disease: better medical therapy, improved surgical procedures
and the development of minimally invasive techniques.
From a historical perspective, the main treatment option of hepatic hydatid disease was the
open surgical approach with side packing and several radical or more conservative surgical
techniques [96, 99]. This terminology in literature might be confusing. Conservative surgery
means that tissue-sparing techniques are used; the hydatid cyst is evacuated and the pericyst
is left in situ, while in radical procedures both the cyst and the pericyst are removed. The most
common conservative techniques include simple tube drainage, marsupialization, capiton‐
nage, deroofing, partial cystectomy or open or closed total cystectomy with or without
omentoplasty. Conservative operations have good results regarding blood loss and length of
hospital stay [103, 104]. In contrast, the cyst content and the entire pericystic membrane are
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removed in radical procedures; a total pericystectomy or liver resection (hemihepatectomy or
lobectomy) is performed [90, 94, 101, 104].
In surgical interventions of hepatic hydatid cysts, complete removal of the parasite should be
performed. Also, prevention of intraoperative spilling of cyst content and saving healthy
hepatic issue is of utmost importance [91, 93, 96]. Spilling could not only lead to recurrence of
hydatid disease, it could also lead to anaphylactic shock before the introduction of the
antihelmintic drugs. Therefore, surgeons need to perform procedures with a focus on safe and
complete exposure of the cyst, safe decompression of the cyst, safe evacuation of the cyst
contents, sterilization of the cyst, treatment of biliary complications and management of the
remaining cyst cavity. Especially in non-endemic areas where the number of operations is low,
the technique needs to be safe and easily reproducible, with a low complication rate. In the
former century, hydatid disease was operated with a high risk of morbidity and recurrence,
possibly due to the spilling of cyst content during the operation. In the 1970s, Saidi developed
a special cone, which was frozen to the cyst in order to reduce the risk of spilling cyst contents.
This cone also simplified the disinfection of the cyst cavity [105]. Recently, this old treatment,
also known as the ‘frozen seal method’, was evaluated in a non-endemic area and it was
concluded to be an effective surgical treatment for hepatic hydatid disease [104]. In this
retrospective study, 112 consecutive patients were treated surgically with the ‘frozen seal’
method for hydatid disease between 1981 and 2007. Recurrence rate was observed in 9 (8%)
patients and morbidity occurred in twenty patients (17.9%). More importantly, no mortality
was observed in this study of more than 25 years of surgically treated ‘echinococcosis'. It was
concluded that this surgical method used in the past century was still safe and effective in the
new millennium. This technique is especially useful in non-endemic areas as it provides high
efficacy and low morbidity rates.
Apart from the ‘frozen-seal method’, surgical treatment options may vary from conservative
treatment (cystectomy) to radical treatment (complete open resection) to laparoscopic techni‐
ques. The debate on best surgical treatment is still ongoing: should this be conservative surgery
or radical surgery in which the cyst is totally removed including the pericyst by total pericys‐
tectomy or partial hepatectomy or should it be the open or laparoscopic approach [101, 102].
4.2. Percutaneous treatments
With the introduction of antihelmintic drugs, new possibilities for treatment arose. By using
this medication, the risk of anaphylaxis became smaller and percutaneous treatments were
developed. One of these treatments for hydatid disease is PAIR: Percutaneous Aspiration,
Injection and Re-aspiration. In a recent meta-analysis of operative versus non-operative
treatment (PAIR) of hepatic echinococcosis [92], PAIR plus chemotherapy proved to be
superior compared to surgery. The meta-analysis showed that PAIR was associated with
improved efficacy, lower rates of morbidity, mortality, disease recurrence and shorter hospital
stay [92].
In conclusion, the main treatment options for hepatic cystic echinococcosis are threefold:
medical therapy, surgery and percutaneous drainage (Puncture Aspiration Injection and
Reaspiration, also known as PAIR) or a combination of these therapies [91, 92, 100]. In the last
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revision of the WHO IWGE it was stated that surgery remains the cornerstone of treatment of
hydatid disease, since it has the potential to remove the hydatid cyst and lead to complete cure.
However, it is advised to evaluate surgical treatment carefully against other less invasive
options such as percutaneous interventions. [88]
5. Improvements in pre-operative planning
An important way to improve the outcome in liver surgery is to prevent liver resection related
complications. One of the main feared complications in liver surgery remains postresectional
liver failure. This major complication may occur if the extent of tumour involvement requires
major liver resection (3 or more segments), leaving a small postoperative remnant liver [3, 106,
107]. Due to impaired liver function this may even result in mortality. Obviously, limiting the
liver resection, in order to leave enough liver remnant volume for proper function of the liver,
can prevent this. However, major hepatectomies are performed increasingly often, mainly
because indications for liver resection are continuously being extended. Former contraindica‐
tions such as bilobar disease, number of metastases and even extrahepatic disease have been
abandoned gradually and compromised liver function may be expected after aggressive
induction chemotherapy. Consequently, postoperative remnant liver volume and function
have become the main determinants of respectability [108-110]. In order to improve outcome
in extended resections and thus to prevent postoperative liver failure after liver resection, a
reliable volumetric assessment of the part of the liver to be resected as well as future residual
liver volume should be a critical part of preoperative evaluation particularly. The safety of
liver resection may increase if an estimate of minimal remnant liver volume is obtained via
CT-volumetry [106, 111].
The utility of existing professional image-processing software is often limited by costs, lack of
flexibility and specific hardware requirements such as coupling to a CT-scanner. In addition,
the intended operation should be known to the investigator to predict the remnant liver
volume accurately and requires the expertise of a liver surgeon. Therefore, CT-volumetry has
hitherto been a multidisciplinary modality requiring the efforts of dedicated surgeons and
radiologists and expensive software. Prospective CT-volumetric analysis of the liver on a
Personal Computer performed by the operating surgeon in patients undergoing major liver
would greatly enhance this preoperative assessment. ImageJ is a free, open-source Java-based
image processing software programme developed by the National Institute of Health (NIH)
and may be used for this purpose [112]. OsiriX® is Apple’s version for image analysis and has
been tested for CT volumetry of the liver [113]. It is also a freely available, user-friendly
software system, which can be used for virtual liver resections and volumetric analysis [113].
As more major liver resections are performed, it is becoming more important to perform liver
volumetry. Recently, these two open source image processing software packages were
investigated to measure prospectively the remnant liver volume in order to reduce the risk of
post-resectional liver failure. Volumes of total liver, tumour and future resection specimen of
the included patients were measured preoperatively with ImageJ and OsiriX by two surgeons
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and a surgical trainee [114]. Results were compared with the actual weights of resected
specimens and the measurements of the radiologist using professional CT scanner-linked
Aquarius iNtuition® software. It was concluded that the prospective hepatic CT-volumetry
with ImageJ or OsiriX® was reliable and can be accurately used on a Personal Computer by
non-radiologists. ImageJ and OsiriX® yield results comparable to professional radiological
software iNtuition®.
6. Minimally invasive surgery
To minimize the damage of treatment, laparoscopic surgery was introduced to avoid large in‐
cisions for many gastrointestinal operations in the previous century. After the first laparoscop‐
ic  cholecystectomy in  1987  [115],  the  number  of  indications  for  this  minimally  invasive
approach increased. The outcome has encouraged surgeons to develop a laparoscopic techni‐
que for many procedures including liver resections [116]. Although this type of surgery is tech‐
nically more demanding and thereby time-consuming [117, 118], it proved to be beneficial for
patients with less pain and better recovery compared to open liver surgery [119-121].
6.1. The history of laparoscopic surgery
The fundamentals of laparoscopic surgery were laid down in the early twentieth century when
the German surgeon Kelling reported on the endoscopic visualization of the peritoneal cavity
in an anesthetized dog using a Nitze cystoscope (1887) in 1902 [122]. Following the introduction
of endoscopic inspection of the abdominal contents in an animal model, fellow countryman
Jacobeus started experimenting with laparoscopy in human cadavers as well asliving humans.
In 1911 he reported on 80 laparoscopic examinations of the abdominal cavity [123, 124]. In the
years thereafter the laparoscopic approach was enhanced with the introduction of illumination
techniques, advancement in lens systems, the use of more than one single trocar and induction
of pneumoperitoneum (Goetze and Veress). The era of therapeutic laparoscopy was then born,
making it possible to minimize damage of treatment and avoid large incisions for many
gastrointestinal operations. However, it was not until 1987 that the first laparoscopic chole‐
cystectomy was performed [115].
At first, liver surgery was thought to be unsuitable for laparoscopic techniques since it might
impose the risk of gas embolisms and major blood loss during transection of the liver. Also,
sceptics pointed out the suspected risk of trocar site metastases in skin incisions. Gradually,
as some expert centres progressively reported feasibility and safety, it became more popular.
This novel approach for liver resections was introduced during the 1990s. At first the procedure
was only used for diagnostic laparoscopies and liver biopsies, later indications were extended
to fenestration of liver cysts and anatomic liver resections. In 1992, Gagner et al. reported the
first laparoscopic wedge resection of the liver. Only three years later, Cuesta et al. were the
first to perform two cases of limited laparoscopic liver surgery of segment II and IV in the
Netherlands [125]. The first laparoscopic left lateral bisegmentectomy of the liver was per‐
formed by the group of Azagra [126]. Since then, several studies have reported the feasibility
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and safety of laparoscopic resections for liver tumours in centres with extensive experience in
both hepatobiliary surgery and laparoscopic surgery [116, 117, 127-130].
However, after its introduction, laparoscopic liver resection remained challenging because of
the difficulties concerning safe mobilization and exposure of this fragile and heavy organ.
Therefore, in the beginning only superficial and peripheral lesions in anterolateral segments
were selected for the laparosopic approach. In recent times, centres with extensive experience
in laparoscopy and hepatic surgery have also performed major hepatic resections laparoscop‐
ically with satisfactory outcomes. Importantly, no evidence of a compromised oncological
clearance in laparoscopic liver resection has hitherto been found [120]
6.2. Advantages of the laparoscopic technique
The laparoscopic approach is said to have shifted the pain of the patient to the surgeon, as the
latter had to obtain new operative skills and more demanding techniques. In fact laparoscopic
surgery is a totally different concept of surgery. The conventional three-dimensional field is
inherently two-dimensional, and the tactile feedback is impaired as compared to open surgery.
Moreover, a full ambidexterity is required, as well as the skills to manipulate fragile structures
with long instruments under minimal tactile feedback. Also, the surgeon becomes even more
dependent on his team and instruments, as he will need experienced assistance for traction
and camerawork and needs to trust the material even more compared to open surgery. For
patients the most important presumed advantages of the laparoscopic procedure are reduced
blood loss [119, 120], less postoperative pain [118, 127, 131], earlier functional recovery [127,
130], shorter postoperative hospital stay [118, 120, 121, 127, 130-132] and improved cosmetic
aspects [127, 130]. Reoperations are reported to be easier due to reduced adhesions [127,
130-132]. Also, open-close procedures with large incisions can be avoided if peritoneal
metastases are detected at laparoscopy.
However, up till now no randomised controlled trials comparing the open and laparoscopic
liver resection technique have been reported. This may well be one of the reasons why many
surgeons remained reluctant to incorporate this new laparoscopic approach. The currently
available evidence is primarily based on case-series and identifies a technique that is repro‐
ducible with limited morbidity and mortality. In a consensus statement on laparoscopic liver
resections, Buell J et al [133] concluded that resection of segments 2 and 3 by the laparoscopic
approach should be the standard of care. In that same year a large international study reported
comparable encouraging results concerning the superiority of laparoscopic liver resections in
terms of complications from 109 patients: the complication rate was only 12% and there were
no perioperative deaths [134]. Median hospital length of stay was 4 days. Negative margins
were achieved in 94.4% of patients.
Overall survival rates and disease-free survival rates for the entire series were 50% and 43%
at 5-year respectively. It was concluded that laparoscopic liver resection for colorectal meta‐
stases was safe, feasible and comparable to open liver resection for both minor and major liver
resections in oncologic surgery. This is confirmed in a recent meta-analysis on short and long-
term outcomes after laparoscopic and open resection. This study included a total of 26 studies,
incorporating a population of 1678 patients [135]. Although laparoscopic liver resections
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resulted in longer operation time, most endpoints were superior for the laparoscopic approach
compared with open resection, including reduced blood loss, portal clamp time, overall and
liver specific complications, ileus and length of hospital stay. As for the long-term outcomes,
no difference was found for oncologic outcomes between the laparoscopic and open surgical
techniques. Therefore, it was concluded that the laparoscopic liver resection was a feasible
alternative to open surgery in experienced hands [135].
7. Enhanced Recovery After Surgery (ERAS) or fast-track liver surgery
Another recent development in elective liver surgery is the introduction of Enhanced Recovery
After Surgery (ERAS) programmes, also referred to as fast track perioperative care. These
multimodal enhanced recovery programmes proved to be beneficial in open colonic and liver
surgery [136, 137]. The multimodal recovery programme is evidence based and combines
several interventions in perioperative care to reduce the stress response and organ dysfunction
with a focus on enhancing recovery [137, 138]. In patients undergoing colorectal surgery, the
ERAS® programme enabled earlier recovery and consequently shorter length of hospital stay
[137-140]. Also, reduction of postoperative morbidity in patients undergoing intestinal
resection was reported [141-144]. In other fields of elective surgery similar programmes have
also shown a reduction in hospital stay of several days [145, 146].
One of the pioneers of the fast track colonic surgery is the Danish surgeon Henrik Kehlet. He
treated 60 consecutive patients with colonic resection in a fast track surgery programme and
reported a median postoperative hospital stay of 2 days. At that time, patients undergoing a
colonic resection usually required 5 to 10 days postoperative hospital stay [147, 148]. Previ‐
ously, he stressed the importance of a multimodal approach in order to improve rehabilitation
after surgery (figure 6) [149]. This rehabilitation programme after surgery combined a number
of interventions to reduce stress of the surgical intervention, risk of organ dysfunction and loss
of functional capacity. Stress induced organ dysfunction, pain, nausea and vomiting, ileus,
hypoxemia and sleep disturbances, immobilisation and semi-starvation had to be reduced.
Factors were identified that contribute to postoperative functional deterioration. These were
actually traditional postoperative care principles such as use of drains, nasogastric tubes,
fasting regimes and bed rest. Kehlet initiated a multimodal programme that abandoned the
traditional care principles and introduced innovations such as: carbohydrate loading before
surgery, regional anaesthetic techniques, maintenance of normal temperature during surgery,
minimally invasive or laparoscopic surgical techniques, optimal treatment of postoperative
pain and prophylaxis of nausea and vomiting [139, 150]. This programme improved postop‐
erative recovery, physical performance and pulmonary function and reduced hospital length
of stay [142].
In collaboration with Kehlet, the Enhanced Recovery After Surgery (ERAS) group was initiated
to investigate the perioperative care in four other hospitals (Royal Infirmary, Edinburgh, UK,
The Karolinska Institutet at Ersta Hospital, Stockholm, Sweden, the University Hospital of
Nothern Norway, Tromso, Noway and Maastricht University Medical Centre) [151]. Thus,
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with Kehlet’s programme as a starting point, a new evidence based programme was developed
incorporating different aspects leading to faster recovery. Preoperative counselling, perioper‐
ative intravenous fluid restriction, optimal pain relief preferably without the use of opioid
analgesia, early oral nutrition, enforced mobilisation, no nasogastric tubes and no drains are
the key elements of this protocol (figure 7). Since the colonic programme showed improve‐
ments in recovery, the liver surgeons of the ERAS® group (Maastricht, Edinburgh and Tromso)
set up an ERAS-programme for every patient undergoing open liver resection [136]
(www.erassociety.org).
So far, the ERAS programmes have shown promising results with respect to improved
recovery and outcome in open elective colorectal and liver surgery [136, 137]. One of the first
studies on ERAS for liver surgery showed that the majority of patients treated within this
multimodal enhanced recovery programme tolerated fluid within four hours of surgery and
a normal diet one day after surgery. As an effect of the accelerated functional recovery, these
patients were discharged two days earlier than the patients treated with traditional care,
without significant differences in readmission, morbidity and mortality rates [136].
These results were confirmed in a recent systematic review including seven studies on fast-
track programmes for hepatopancreatic resections, incorporating more than 550 patients
treated in fast track setting [152]. This study showed that the primary hospital stay was reduced
significantly after the introduction of a multimodal perioperative care programme for open
liver surgery [152]. Moreover, there were no significant differences in rates of readmission,
morbidity and mortality.
7.1. Synergy of ERAS and laparoscopic liver surgery
For solid tumours in the liver, the open approach for resection is gradually replaced by the
laparoscopic technique in many expert centres worldwide. The results, mostly from cohort
studies, suggest benefits with notably shorter postoperative stay [120]. Recently, the added
value of a fast-track ERAS-programme in laparoscopic liver surgery specifically has been
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Figure 6. Multimodal interventions may lead to a reduction in postoperative morbidity and improved recovery. [149]
Figure adapted with kind permission from Kehlet et al. 1997.
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elucidated [153]. A group consisting of patients undergoing laparoscopic liver resections in an
ERAS-setting was compared with historical data from consecutive laparoscopic liver resec‐
tions performed either in that same centre before the introduction of the ERAS-programme or
in other major liver centres in the Netherlands performing laparoscopic liver surgery in a
traditional perioperative care programme.
• A significant difference with a median of two days in time to full functional recovery was
observed between the ERAS-treated group and the traditional care group. The difference in
median hospital length of stay (LOS) of two days between these two groups did not attain
significance. The authors suggested that it was probably due to the small number of patients
in this multicentre pilot-study. Apart from faster functional recovery in patients in the
enhanced recovery group, this study also showed reduced blood loss in this group.
• As from a historical perspective, this multicentre fast-track laparoscopic liver resection
study was the first study to explore the effect of ERAS and laparoscopic surgery. This small
study suggests that a multimodal enhanced recovery programme for laparoscopic liver
surgery is feasible, safe and may lead to accelerated functional recovery and reduction in
length of hospital stay. With these findings it may be concluded that the additional effect of
ERAS leads to an improvement of liver surgery and outcome.
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Figure 7. Important elements of the Enhanced Recovery After Surgery programme. [138] Figure adapted with kind
permission from Fearon et al. 2005.
8. Recent developments in hepatic malignancies
As for the recent developments in the treatment of liver diseases, these can be mainly divided
into surgical and non-surgical treatment modalities. Developments in surgical treatment can
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be divided in true surgical and perioperative care improvements. The focus is on the surgical
treatments in this chapter, but some thoughts will also be spent on the non-surgical treatment
modalities, an interesting and expanding field of expertise.
For malignant liver tumours, the majority of which are colorectal liver metastases, the main
concern is the resectability if colorectal cancer is diagnosed. Colorectal cancer is one of the most
common causes of cancer related death worldwide [38] and more than half of patients with
colorectal cancer will develop liver metastases [39]. Unfortunately, only 20% of the patients
can be treated with surgical resection of these liver metastases [154]. The remaining 80% of the
patients present with lesions, which are not suitable for a safe resection. This can be caused by
large diameters of the lesions, location of the lesion near vascular and biliary structures and
extrahepatic disease. Also, the number of lesions can be the cause of non-resectability: resection
can only be carried out safely if 25-30% of functioning liver remains after resection [155]. The
non-surgical treatment by means of chemotherapy for the patients with unresected liver
metastases has proven very successful in decreasing the size and number of liver lesions. It
was shown that new chemotherapy regimens could change the previously unresectable liver
metastases into resectable liver disease [156]. With neoadjuvant chemotherapy more patients
with colorectal liver metastases can be offered a treatment with curative intent [156]. It was
concluded that neoadjuvant chemotherapy enables liver resection in some patients with
initially unresectable colorectal metastases. Long-term survival proved to be similar to that
reported for a priori surgical candidates [56]. As for the future perspective of chemotherapy,
neoadjuvant treatment will improve curability and long-term survival for selected patients.
Other non-surgical therapies for malignant liver disease are external irradiation (whole liver
irradiation) [157, 158], stereotactic liver irradiation [159-162] and injectable small radioactive
particles that irradiate the tumours within the liver (e.g. Yttrium-90(90Y) radio-embolisation
[163, 164], radioactive holmium microspheres [165, 166]). These modalities may have curative
potential but future studies have to be awaited. Another attractive field of development are
the thermal ablative therapies for unresectable liver metastases. These ablative thermal
therapies can be used either percutaneously or in adjunct with surgery and have shown to
decrease focal liver lesions [167-170]. Microwave ablation is a tumour destruction method to
treat patients with unresectable liver lesions [169]. It can be used with a single insertion of the
probe and it was shown to be a safe and effective method for treating unresectable hepatic
tumours, with a low rate of local recurrence [170]. Overall survival is comparable to alternative
ablation modalities [169].
8.1. Future perspectives
As for surgical treatments, different treatment strategies have been developed to increase the
number of patients suitable for surgery as described earlier. Current research has focussed on
improving resectability in terms of the quantity of resected liver tissue, but at the same time
studies focussed on reducing perioperative distress in patients undergoing liver resections by
multimodal perioperative treatment protocols and minimally invasive surgery. Since the
introduction of laparoscopic liver surgery in 1992, more liver resections have been performed
with this minimally invasive approach for primary and secondary malignant liver lesions [129,
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134, 153]. For future perspectives, some gain might be expected from even less invasive
modalities as the first reports on single incision laparoscopic resections have been presented
[171-173]. Also, a two-stage laparoscopic approach for malignant liver disease and the robotic
approach for liver resections have been published [174-176].
As discussed previously in this chapter, the recent developments in liver surgery include the
introduction of laparoscopic surgery and enhanced recovery programmes, which focus on
improvement of postoperative recovery and/or shorter hospital length of stay. A significantly
accelerated recovery after open liver resection was previously reported if patients were
managed within a multimodal ERAS protocol. Median hospital length of stay was reduced
from 8 to 6 days (25%) [136]. Moreover, since there was a delay between recovery and discharge
of the patients a further reduction of stay should be possible. Regarding the results of previous,
non-randomised randomized studies and case series, it seems that laparoscopic left lateral liver
sectionectomy is associated with shorter hospital length of stay, less postoperative pain, better
quality of life and a faster recovery [177]. In most trials aiming at a reduction of hospital length
of stay, surgery and/or perioperative management are not standardised. No randomised trials
have hitherto been reported to study the added value of ERAS and/or laparoscopy for liver
surgery. There is a need for a randomised controlled trial covering these aspects of improving
the recovery and outcome of liver surgery.
9. Liver transplantation
Liver transplantation surgery is one of the main advances in hepatic surgery. Until recently,
it was considered to be too complex, since artificial organ support, like haemodialysis in renal
failure, was considered impossible. The term liver transplantation was first used in an article
of Welch (NY, USA) in 1955 [178]. The first experimental liver transplantation surgery was
performed on animals (dogs) in the 1950s and 1960s by Starzl (Denver, USA, figure 8) and
Moore (Boston, USA). These transplantations failed as a result of the stagnation of blood in the
mesenterial vessels and a lack of blood flow to the heart after clamping the inferior vena cava.
Methods for a venovenous bypass to the superior vena cava were developed, whereupon
transplantation seemed to be realizable. Despite the fact that immunosuppressive drugs
became available at that time, most grafts were rejected though. As a result, only a few dogs
survived [178-181].
9.1. The history of liver transplantation in humans
In 1963 the first three orthotropic liver transplantations in humans were performed by Starzl
and colleagues. All livers came from non-heart beating donors (NHBDs). Although the first
transplantation was performed in one session, the second and third took two sessions; the first
session was designated for the preparation of the removal of the liver from the donor and in
the second session the liver was removed and transplanted in the recipient after the donor
died. In the donor patient extracorporeal perfusion was performed via the femoral vein and
artery. The structures in the hepatoduodenal ligament were cut through and the liver was
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taken out with the vena cava. In the recipient the liver was taken out likewise and a venovenous
bypass was made to circumvent the hemodynamic effects of clamping the vena cava [182].
Immunosuppressive therapy, by ways of azathioprine and prednisone, was applied since these
drugs were proven to be effective in renal transplantation [183]. The first patient was a three-
year-old boy with biliary atresia who died during the operation due to haemorrhage, the
second and third patient were adult males suffering from liver cancer who died 7 and 22 days
postoperative, as a result of lung embolism [182]. Starzl then decided to take a break to have
a period of reflection. Four years later, in 1967, he decided to try again and he then performed
the first successful liver transplantation with a one-year-survival [184].
Infections were frequently occurring complications [185]. The most important complication of
these early transplantations however, was severe blood loss. This was caused by manipulation
of abdominal veins which had been under great pressures due to chronic liver diseases [179].
The first orthotropic liver transplantation in Europe was performed in Cambridge in 1968 by
Calne [186]. In the same year consensus was achieved concerning the concept of cerebral death.
From that moment on, heart-beating donation with donor organs originating from heart
beating, brain dead donors was possible [184]. Nowadays the above described venovenous
bypass has been abandoned in many centres in Europe. Since the beginning of the 1990’s most
centres use the so called ‘piggyback’ technique. The liver is exposed from the vena cava after
which the vena cava is partially clamped longitudinally. After the liver has been flushed with
albumin to remove ischemic waste products, a side-to-side cavocaval anastomosis is made. In
doing so, the hemodynamic stability of the patient is guaranteed. Then, the portal liaison is
Figure 8. Thomas E. Starzl (1926).
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made by an end-to-end anastomosis, the liver is perfused and the arterial anastomosis is made.
Finally the biliary ducts are connected by way of end-to-end anastomosis and in case of
sclerosis a Roux-en-Y-reconstruction [187, 188].
9.2. Immunsuppressive drugs
The discovery and appliance of immunosuppressive medication to prevent graft rejection has
been an important development in transplantation surgery. Despite the fact that graft rejection
has been a serious problem during the early years of liver transplantation, many transplanted
patients survived more than 20 years as a result of this immunosuppressive therapy with an
azathioprine-prednisone cocktail. Some time later, a third immunosuppressive drug, antilym‐
phocyte-globulin (ALG), was added to the therapy [178, 189, 190]. Then Calne discovered the
possibility to use cyclosporin A, a calcineurin inhibitor, as an immunosuppressive drug [191].
After cyclosporine A was first used in renal transplantations in 1980 [192], it was then applied
in liver transplantation and the one-year-survival rate in liver transplantation turned out to
have increased to 80% [193]. Currently Tacrolimus (FK 506), also a calcineurin inhibitor, is
recommended [194-197]. A detailed overview of the development and the working mecha‐
nisms of immunosuppressive drugs is beyond the scope of this chapter.
9.3. Split liver transplantation
The concept of liver transplantation has been developed gradually, which made it a widely
accepted treatment with an increasing number of indications and good survival rates. This
caused a shortage of donor organs, especially among children, and long waiting lists. New
techniques had to be developed to answer to this growing demand. In 1984 Bismuth developed
the reduced-size adult liver transplantation; an adult left lobe was transplanted into a child.
This is a unique method, only applicable in liver transplantation surgery because of its
segmental anatomy with independently functioning parts [198]. Further development of
segmental liver surgery resulted in the split liver transplantation (SLT); the donor liver is
splitted, the left part (segment 2 and 3 with the common hepatic duct and common hepatic
artery) is transplanted into a child and the right part (segment 1, 4-7 with the vena cava) into
an adult. In the recipient of the left liver part, the vena cava is preserved and an anastomosis
is made with the left hepatic vein. The other anastomoses are made in the usual way. In the
recipient of the right liver part, an anastomosis is made between the right hepatic artery of the
donor liver and the common hepatic artery of the recipient by means of a saphenous vein
interposition graft. Two intrahepatic biliary ducts are connected with the jejunum through a
Roux-en-Y loop, the other anastomosis are executed in the usual way [199]. There are two ways
of splitting the liver, in situ and ex situ, both with its (dis)advantages. The main disadvantage
of in situ splitting is a longer operation time and therefore the need for a haemodynamically
stable patient. Splitting ex situ on the other hand, is done in blood vacuum. The time of cold
ischemia is longer and it is harder to distinguish structures from each other. Hence, strict donor
selection is essential and there is a trend to only select donors <50 years or who are heamody‐
namically stable. Bile spill is reported as the most common complication. Other complications
are an insufficient hepatic artery, portal vein thrombosis, intra-abdominal haemorrhage and
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gastro-intestinal bleeding. Mortality rates of 11% have been reported [200, 201]. In Europe, in
2003, 89% of all liver transplantations consisted of full-size transplantations, 4% of SLT’s and
5% of reduced-liver transplantations. In specialized centres, the survival rates of these
techniques are comparable to the survival rates of regular transplantation [202].
9.4. Living-donor liver transplantation (LDLT)
In 1987 Raia (Brazil) developed the living-donor liver transplantation (LDLT) from an adult
into a child. The operation itself was successful, but the recipient child died due to a transfusion
reaction [203]. The first successful LDLT from mother to son with a left liver lobe was per‐
formed in Australia by Strong [204] after which this method was refined by many other
pioneers. It is a very difficult operation technique in which precise knowledge of the anatomy
is a prerequisite. Because of a great shortage of donor organs in Asia, most experience with
the LDLT was gained there. Innovative surgery was the only possibility to tide over this
shortage. These techniques seemed to be effective; waiting-list-related mortality among
children was reduced to almost 0% [205, 206]. Since Fan (Honk Kong) introduced the adult-
to-adult living liver transplantation with a hemi-liver (dependent on the size of donor and
recipient either the right or left lobe is transplanted) in 1997, the availability of donor livers for
adults increased [207].
The main advantage of LDLT is limitation of warm ischemia because operations can be planned
simultaneously [208]. The results of LDLT are comparable to those of regular (orthotopic) liver
transplantation. According to the Japanese Liver Transplantation Society the 5-year-survival
rate in adults is 69%. In children this rate is significantly higher with 83% [205]. In the USA the
reported survival rate in adults is 80% [209]. In Europe, a 5-year-survival of 75% (80% in
children, 66% in adults) between 1991 and 2001 was reported [202, 205]. In Europe, in 2003,
only 1.6% of all liver transplantations consisted of LDLT [202].
The main disadvantages of  this  technique are the potential  complications in the healthy
donor  and  the  psychological  impact  [189,  210].  The  number  of  postoperative  complica‐
tions in donors is reported to be 20%. Worldwide 10 (0.15%) donor deaths have been re‐
ported. The mortality rate in Europe, in 2010, was 0.2% (6/2906) [211]. The critical period
for death and primary dysfunction is within 6 months from the operation. In a graft too
small for the recipient, dysfunction will develop with hyperbilirubinemia, ascites and liv‐
er  function failure resulting in coagulation disorders and renal  failure.  A graft  which is
too big for the recipient will  result  in necrosis because of shortage in blood supply.  Be‐
sides good patient selection, proper calculation to determine the correct graft size has to
be done to prevent these complications [189, 205].
9.5. Improving survival
In 1997 the Institute of Medicine (USA) declared NHBD-organs to be medically effective and
ethically acceptable [178]. From that time on, the trend exists to use NHBD- and marginal
organs (livers with steatosis) again to tide over the shortage of donor organs and shorten the
waiting lists. Marginal livers are associated with primary non-function [212]. The main
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problem of NHBD’s is the prolonged period of warm ischemia. A distinction between
controlled NHBD’s (Maastricht type I and II) and uncontrolled NHBD’s (Maastricht type III
and IV) is made. Controlled NHBD’s provide organs with less chance on ischemic damage and
a greater chance on good post-transplantation function. In this group of patients a controlled
end of vital support takes place after which a circulation stop occurs. In most cases the patient
is already in the operation theatre with a transplantation team on site. This way, the time of
warm ischemia is minimalised. In uncontrolled NHBD’s a non-foreseen circulation stop
occurs, usually before arrival in the hospital, possibly followed by resuscitation. A variable
period of warm ischemia occurs with a higher chance on complications [212, 213]. Cold
ischemia causes damage of sinusoidal endothelial cells and warm ischemia of hepatocytes
[214]. Besides, warm ischemia intensifies the effects of cold ischemia and predisposes for a
higher incidence of ischemic biliary structures both on the short and the long term. In such
cases, re-transplantation might be needed [215]. Since the University of Wisconsin Solution,
introduced in 1988, has become the golden standard for cooling donor organs and the
maximum period of cold ischemia has been limited to 12 hours, ischemic damage due to cold
ischemia has been reduced drastically with increased graft survival [202]. However, as a
consequence of warm ischemia graft survival is lower in NHBD’s compared to heart-beating
donors with a 3-year-survival of 63.3% versus 72.1%. The risk of primary non-function is also
significantly higher among NHBD’s: 11.8% versus 6.4% [189, 216]. For this reason NHBD’s can
be used to overcome organ shortage, on condition that strict criteria are maintained: strict
donor (<60 years) and recipient (haemodynamically stable and not intubated) selection, minor
warm (<30 minutes) and cold (<8 hours) ischemia, no extensive steatosis of the donor liver and
the use of at most one inotropic drug (to prevent hypotension and thus hypoperfusion) [212].
With the gradual progression in surgical competences, management of postoperative com‐
plications  and the  development  of  immunosuppressive  drugs  to  prevent  graft  rejection,
liver transplantation has nowadays become a widely accepted treatment for an increasing
number of indications and it has become the golden standard for patients with irreversi‐
ble decompensated chronic liver failure (e.g. as a result of cirrhosis or hepatocellular can‐
cer)  and  acute  liver  failure  (e.g.  as  a  result  of  hepatic  viruses  or  intoxication  with
medication). In the early days cancer was the most common indication for liver transplan‐
tation. In Europe, however, with 50% the most important indication for liver transplanta‐
tion was cirrhosis (of which 24% was caused by a virus (especially Hepatitis C) and 18%
by  alcohol  abuse),  followed  by  pathology  of  the  biliary  tract  (13%),  primary  liver  tu‐
mours (10%), of which hepatocellular cancer is the most common, and acute liver failure
(9%), with fulminant viral hepatitis as the most important cause. The most important indi‐
cations in children are biliary atresia (56%) and metabolic diseases (21%) [202]. Due to the
development of different methods and techniques, organ shortage has been reduced and
waiting lists have been shortened. Hence, one can conclude that liver transplantation is a
recent and very important advancement, which has expanded in a short time. It is a per‐
fect example of modern and innovative medical practice, in which the challenge remains
to find solutions to new problems time after time.
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